Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 19/20 | 0.64 |
| ▸ | BACE2 | Q9Y5Z0 | 11/20 | 0.64 |
| ▸ | CTSD | P07339 | 5/20 | 0.60 |
| ▸ | APP | P05067 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3510224 | 1.00 | BACE1 (0.64) | BACE1BACE2CTSDAPP | |
| SCHEMBL3510372 | 0.91 | BACE1 (0.62) | BACE1BACE2CTSDAPP | |
| SCHEMBL4218263 | 0.91 | BACE1 (0.62) | BACE1BACE2CTSDAPP | |
| SCHEMBL2248494 | 0.90 | BACE1 (0.71) | BACE1BACE2 | |
| SCHEMBL13228791 | 0.90 | BACE2 (0.61) | BACE1BACE2CTSDAPP | |
| SCHEMBL4206841 | 0.90 | BACE2 (0.61) | BACE1BACE2CTSDAPP | |
| SCHEMBL8238978 | 0.89 | BACE1 (0.55) | BACE1BACE2CTSDAPP | |
| SCHEMBL13229615 | 0.88 | BACE1 (0.55) | BACE1BACE2CTSDAPP | |
| SCHEMBL13229347 | 0.87 | BACE1 (0.51) | BACE1BACE2CTSDAPP | |
| SCHEMBL8249481 | 0.84 | BACE1 (0.88) | BACE1BACE2CTSDAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140066488-A1 | Inhibitors of Memapsin 2 Cleavage for the Treatment of Alzheimer's Disease | PURDUE RESEARCH FOUNDATION (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130102593-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2013-04-25 | — | — | US | disclosed |
| US-20130102593-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2013-04-25 | — | — | US | disclosed |
| US-20130102593-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2013-04-25 | — | — | US | disclosed |
| US-20130059840-A1 | SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059840-A1 | SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059840-A1 | SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120295894-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BILCER GEOFFREY M (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295894-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BILCER GEOFFREY M (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295894-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BILCER GEOFFREY M (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2009015369-A2 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| EP-1942101-A1 | SECRETASE INHIBITOR | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-7348356-B2 | Phenylcarboxamide beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK & CO., INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348356-B2 | Phenylcarboxamide beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK & CO., INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348448-B2 | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK & CO., INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348448-B2 | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK & CO., INC. (US) | 2008-03-25 | — | — | US | disclosed |
| WO-2007017511-A2 | COMPOUNDS FOR TREATING ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017510-A2 | ISOPHTHALIC ACID DIAMIDES FOR TREATING ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2005004803-A2 | PHENYLCARBOXYLATE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004043916-A1 | PHENYLCARBOXAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059840-A1 | SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE1, BACE2, GSAP | BACE1 1/4885BACE2 2/4885CTSD 39/4885 |
| US-20120295894-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 27/4885 |
| US-20140066488-A1 | Inhibitors of Memapsin 2 Cleavage for the Treatment of Alzheimer's Disease | PSEN2, BACE2, PSEN1 | BACE1 5/4885BACE2 2/4885CTSD 209/4885 |
| US-20130102593-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.